[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Lutetium-177 (Lu-177) Market and Pipeline Analysis - Forecast to 2027

February 2020 | 91 pages | ID: LE8E75EE2FFCEN
IQ4I Research & Consultancy Pvt. Ltd.

US$ 3,600.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
“Lutetium-177 Global Market Analysis” gives comprehensive insights on the various Lu-177 based drugs being developed for the treatment of GEP-NET, prostate cancer and other diseases. The report covers marketed products details and also drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on Lu-177 labeled monoclonal antibodies and peptides for various indications that are in clinical trials, FDA and CE approved products (Lutathera).

The report covers the patient population, treatment cost, total addressable market and penetration for GEP-NET and Prostate cancer. It covers list of nuclear reactors that have potential to produce Lu-177 both medium and high flux reactor with their locations all over the world. It also focuses on supply chain analysis and market dynamics (DROT) of Lu-177.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Lu-177 global market. The report also provide strategic insights on some of the molecules which will eventually be launched in the next few years.

Market analysis

In market analysis section, global GEP-NET and Prostate cancer market are indicated along with the Lu-177 treatment eligible patients size, total addressable market (TAM) and demand for Lu-177 isotope are forecasted from 2019 to 2026
  • Lu-177 market dynamics.
  • Lu-177 related deals analysis.
  • Funding scenario in Lu-177 market
  • Market Size and Total addressable market.
Pipeline Analysis

Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified along with current development status & nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development)
  • Pipeline analysis by molecule type
  • Monoclonal Antibodies labeled pipeline analysis
  • Peptide labeled pipeline analysis
  • Pipeline analysis by leading players & their molecule analysis
Key Players Analysis

The key player’s analysis section provides an in-depth understanding of various companies working on Lu-177 and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.

Global key players overview
  • Global key players Pipeline data (discovery, pre-clinical & clinical development)
  • Global key players deals (collaborations, partnership, licensing agreements, grants, funds)
REPORT DESCRIPTION INTRODUCTION

EXECUTIVE SUMMARY

MARKET DYNAMICS (DROT)

SUPPLY CHAIN ANALYSIS

Direct
Indirect

DEALS

Acquisition
Agreement
Partnership
Collaboration

FUNDING SCENARIO

MARKET DATA

TAM and Penetration - GEP-NET (Region)
TAM -Prostate Cancer (Region)

ASSUMPTIONS

PIPELINE ANALYSIS

Development Stage
Indications
Major Players
Molecule Type

RIT BASED PIPELINE ANALYSIS

By Phase
By Indiacation
Clinical trial update on Phase 3 and Phase 2b molecules PRRT BASED PIPELINE ANALYSIS
By Phase
By Indiacation
Clinical trial update on Phase

MAJOR PLAYERS

Company Profiles
Overview, Pipeline

MEDIUM FLUX REACTOR AND LOCATION

HIGH FLUX REACTOR AND LOCATION

SUPPLIERS OF Lu-177
Annual Estimated Production Capacity

REFERENCE


More Publications